- Trial phase
- Phase 3
- Time to market
- Likely 2029 or later, based on the estimated primary completion date of May 2029 for the MAESTRA 2 pivotal trial, assuming positive results and a subsequent regulatory filing.
- Why 4/10
- No hard binary catalyst (PDUFA or pivotal topline readout) is scheduled within the next 12 months; the MAESTRA 2 Phase 3 trial started Dec 2025 with estimated primary completion in May 2029. INCB123667 is a mid-stage pipeline asset at a diversified commercial-stage biotech where it represents a meaningful but not dominant portion of company value, scoring a default 4 per the rubric.
No hard binary catalyst (pivotal readout or FDA decision) is expected for INCB123667 within the next 12 months. The MAESTRA 2 Phase 3 trial started December 2025 with estimated completion in 2029. Investors should watch for interim data updates at medical conferences like ASCO 2027 (June) or ESMO 2027 (October), and for enrollment progress updates in Incyte quarterly earnings calls. Near-term value drivers for INCY stock are more likely to come from approved products (Jakafi, Opzelura) and nearer-term pipeline readouts for other assets like povorcitinib and INCA033989.
Price Chart
Executive Summary
INCB123667 is Incyte's oral, selective CDK2 inhibitor targeting cyclin E1-overexpressing ovarian cancers, currently in Phase 3 development with two ongoing registration-directed trials (MAESTRA 2 in platinum-resistant disease and MAESTRA 3 in first-line maintenance). Early Phase 1 data showed a 33% objective response rate as monotherapy at the optimal dose, and ESMO 2026 data showed a 48% response rate in combination with bevacizumab. INCB123667 is the first CDK2 inhibitor to enter Phase 3, but pivotal readouts are likely years away (estimated completion 2029 for MAESTRA 2). The drug is one of several pipeline assets at Incyte, a diversified biotech with $5.2B+ in annual sales led by Jakafi and Opzelura, so this single asset represents a modest portion of total company value.
How It Works
INCB123667 is an oral pill that blocks CDK2, a protein that helps cancer cells divide and grow. Many ovarian cancers overproduce a partner protein called cyclin E1, making them especially dependent on CDK2. By inhibiting CDK2, the drug stops these cancer cells from multiplying and triggers their death. The drug is designed to be highly selective for CDK2 to avoid side effects on related cellular proteins.
Trial Status
Two Phase 3 trials are recruiting: MAESTRA 2 (NCT07214779), a randomized open-label study vs investigator's choice chemotherapy in ~466 patients with platinum-resistant ovarian cancer with cyclin E1 overexpression, started December 2025. MAESTRA 3 (NCT07797283), a double-blind randomized study of INCB123667 + bevacizumab vs bevacizumab alone as first-line maintenance in ~590 patients, registered September 2026. A Phase 1 monotherapy study (NCT05238922) has completed enrollment with data presented at ASCO 2025 and ESMO 2025/2026.
The Two-Sided Case
Upcoming Catalysts
- Potential interim data updates at medical conferences (ASCO June 2027, ESMO October 2027)
- Enrollment updates for MAESTRA 2 and MAESTRA 3 in quarterly earnings calls
- Phase 1 data from combination studies (bevacizumab, endocrine therapy, CDK4/6 inhibitors)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
INCYTE CORP 8-K INCY ·Originating report